bioRxivMicrobiologyPreprint
A screen of covalent inhibitors in Mycobacterium tuberculosis identifies serine hydrolases involved in lipid metabolism as potential therapeutic targets
B. M. Babin, L. J. Keller, Y. Pinto, V. L. Li, A. Eneim, S. E. Vance, S. M. Terrell, A. S. Bhatt, J. Z. Long, M. Bogyo
Abstract
The increasing incidence of antibiotic-resistant Mycobacterium tuberculosis infections is a global health threat necessitating the development of new antibiotics. Serine hydrolases (SHs) are a promising class of targets because of their importance for the synthesis of the mycobacterial cell envelope. We screened a library of small molecules containing serine-reactive electrophiles and identified narrow spectrum inhibitors of M. tuberculous growth. Using these lead molecules, we performed competitive activity-based protein profiling and identified multiple SH targets, including enzymes with uncharacterized functions. Lipidomic analyses of compound-treated cultures revealed an accumulation of free lipids and a substantial decrease in lipooligosaccharides, linking SH inhibition to defects in cell envelope biogenesis. Mutant analysis revealed a path to resistance via the synthesis of mycocerates, but not through mutations to target enzymes. Our results suggest that simultaneous inhibition of multiple SH enzymes is likely to be an effective therapeutic strategy for the treatment of M. tuberculosis infections.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Exploration of synergistic action of cell wall-degrading enzymes against Mycobacterium tuberculosis
L. van Schie, K. Borgers, … N. Callewaert·bioRxiv·Apr 5, 2021
- Comprehensive identification of β-lactam antibiotic polypharmacology in Mycobacterium tuberculosis
Kaylyn L. Devlin, Emily Hutchinson, … Kimberly E. Beatty·ACS Infectious DiseasesPeer-reviewed·Aug 18, 2025
- MTB-LysB1: A Novel Endolysin Against Multidrug-resistant Mycobacterium tuberculosis
Ritu Arora, Kandasamy Eniyan, … Urmi Bajpai·bioRxiv·Jul 13, 2026
- L-Serine and Palmitoyl CoA control Mycobacterial infection by tweaking protective immune response: A potential host directed therapy for tuberculosis
Niharika Sharma, Rahul Sharma, … Hridayesh Prakash·bioRxiv·Sep 3, 2026
- A competitive activity-based protein profiling platform yields cell wall synthesis inhibitors active against replicating and non-replicating Mycobacterium tuberculosis
M. Li, H. V. Patel, … J. C. Seeliger·bioRxiv·Apr 16, 2021
- Elucidation of the essentiality of lumazine synthase (RibH) for Mycobacterium tuberculosis survival and discovery of potent inhibitors for enhanced antimycobacterial therapy
M. Singh, A. Dhanwal, … R. J. Dey·bioRxiv·Jul 18, 2023